# BEGONIA (NCT03742102)

> A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03742102
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Triple Negative Breast Neoplasms
- Interventions: Durvalumab; Capivasertib; Oleclumab; Paclitaxel; Trastuzumab deruxtecan; Datopotamab deruxtecan
- Enrollment: 243
- Primary outcome: Dose Limiting Toxicity (DLT) Events

## Commentary we found

- YouTube: 71
- Podcasts: 55
- X threads: 26
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=begonia-nct03742102

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03742102", "email": "<work email>"}; the inbox owner confirms by the emailed link.